Want to see RPID full AI Analyst Report?
RPID Stock Chart & Stats
$2.28
-$0.03(-2.88%)
At close: 4:00 PM EST
$2.28
-$0.03(-2.88%)
Day’s Range― - ―
52-Week Range$1.66 - $4.94
Previous CloseN/A
Volume19.55K
Average Volume (3M)253.56K
Market Cap
$85.69M
Enterprise Value$86.04M
Total Cash (Recent Filing)$22.95M
Total Debt (Recent Filing)$23.71M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Jul 31, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding45,322,280
10 Day Avg. Volume146,703
30 Day Avg. Volume253,557
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.90
Price to Sales (P/S)3.86
P/FCF Ratio-4.06
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue2.50
Enterprise Value/Gross Profit20.18
Enterprise Value/Ebitda-1.91
Forecast
1Y Price Target
$6.67Price Target Upside192.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.96
Revenue Forecast (FY)$39.25M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ExpansionA 63% recurring revenue mix and 28% YoY growth indicate a durable revenue base from consumables and service. High attach rates make future top-line less dependent on one-time system sales, supporting predictable cash flows and margin leverage as installed base scales.
Margin Improvement TrajectoryMaterial improvements in product and consumable margins driven by cost reductions and manufacturing productivity point to structural unit-cost improvements. If sustained, these efficiency gains can convert revenue growth into durable gross-margin expansion and reduce the revenue level needed for break-even.
Strategic Commercial PartnershipAn exclusive collaboration with MilliporeSigma broadens distribution, validation support and sourcing options. This partnership can structurally lower customer adoption friction, expand addressable markets and improve sourcing economics, aiding long-term placement and consumable volume growth.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow at this magnitude creates an ongoing funding need and heightens dilution or refinancing risk. Until the business generates positive operating cash, management must secure capital or use credit tranches, stressing long-term funding flexibility.
Rising Leverage And Eroding EquityLeverage rising from prior low levels as equity erodes increases solvency and covenant risk. A higher debt burden reduces financial flexibility, raises interest and refinancing exposure, and makes execution lapses more dangerous for sustaining investments in commercialization and margin programs.
Low Absolute Margins And High Op-exHigh operating expense guidance combined with low current gross margins implies continued operating losses absent faster margin conversion or higher volumes. This structural gap requires sustained execution on placements, consumable growth and cost control to achieve profitability and positive cash generation.
Rapid Micro Biosystems News
RPID FAQ
What was Rapid Micro Biosystems’s price range in the past 12 months?
Rapid Micro Biosystems lowest stock price was $1.66 and its highest was $4.94 in the past 12 months.
What is Rapid Micro Biosystems’s market cap?
Rapid Micro Biosystems’s market cap is $85.69M.
When is Rapid Micro Biosystems’s upcoming earnings report date?
Rapid Micro Biosystems’s upcoming earnings report date is Jul 31, 2026 which is in 26 days.
How were Rapid Micro Biosystems’s earnings last quarter?
Rapid Micro Biosystems released its earnings results on May 13, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.247 by -$0.063.
Is Rapid Micro Biosystems overvalued?
According to Wall Street analysts Rapid Micro Biosystems’s price is currently Undervalued.
Does Rapid Micro Biosystems pay dividends?
Rapid Micro Biosystems does not currently pay dividends.
What is Rapid Micro Biosystems’s EPS estimate?
Rapid Micro Biosystems’s EPS estimate is -0.24.
How many shares outstanding does Rapid Micro Biosystems have?
Rapid Micro Biosystems has 45,322,280 shares outstanding.
What happened to Rapid Micro Biosystems’s price movement after its last earnings report?
Rapid Micro Biosystems reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.247. Following the earnings report the stock price went down -6.452%.
Which hedge fund is a major shareholder of Rapid Micro Biosystems?
Currently, no hedge funds are holding shares in RPID
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapid Micro Biosystems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (192.40% Upside)
$6.67 (192.40% Upside)
Blogger Sentiment
Bullish
RPID Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.4K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.67%
12-Months-Change
Fundamentals
Return on Equity
-131.52%
Trailing 12-Months
Asset Growth
-27.00%
Trailing 12-Months
Company Description
Rapid Micro Biosystems
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
RPID Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but improving picture: revenue, product/consumables growth, recurring revenue expansion, system placements, and a strategic MilliporeSigma partnership are meaningful positives and support long-term margin improvement. However, near-term challenges include low absolute gross margins, a widened net loss, elevated operating expenses, significant Q1 cash burn, and variability in service revenue tied to validation timing. Management reiterated full-year revenue guidance and outlined margin improvement expectations, but execution risk and liquidity depend on achieving planned cost reductions, converting the sales funnel (including MilliporeSigma-driven placements), and unlocking credit facility tranches.View all RPID earnings summariesRPID Stock 12 Month Forecast
Average Price Target
$6.67
▲(192.40% Upside)
Technical Analysis
Ownership Overview
33.01% Insiders
3.09% Mutual Funds
28.12% Other Institutional Investors
33.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---